[A14-23] Vedolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Last updated 15.10.2014
Project no.:
A14-23
Commission:
Commission awarded on 15.07.2014 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-33 | Vedolizumab (antibiotic refractory chronic pouchitis) – Benefit assessment according to §35a Social Code Book V | Commission completed |